Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome

Nef HM, Wiebe J, Schmidt G, Möllmann H, Boeder NF, Dörr O, Bauer T, Blachutzik F, Liebetrau C, Elsässer A, Foin N, Hamm CW (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Herz Springer Verlag (Germany)

Book Volume: 45

Pages Range: 95-104

DOI: 10.1007/s00059-019-4822-7

Abstract

Background: Limited data exist on bioresorbable scaffolds (BRS) in patients with acute coronary syndrome (ACS). The aim of the present study was to evaluate novolimus-eluting BRS (DESolve) as interventional treatment for patients with ACS, and to compare its 12-month outcomes with the everolimus-eluting bioresorbable scaffolds (Absorb). Methods: In this retrospective study, patients with ACS (including unstable angina pectoris, ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction) treated with either the Absorb or the DESolve BRS were evaluated in a 1:1 matched-pair analysis. Major adverse cardiac events (MACE), including death, myocardial infarction, and target lesion revascularization, were evaluated as a major endpoint. The occurrence of scaffold thrombosis was also assessed. Results: A total of 102 patients were eligible for this analysis. The rate of MACE at 12 months was comparable between the Absorb and the DESolve group (8.3% vs. 6.8%, p = 0.738). The occurrence of target lesion revascularization (6.2% vs. 4.7%; p = 0.700) and scaffold thrombosis (4.1% vs. 2.1%; p = 0.580) was comparable as well. All instances of scaffold thrombosis occurred within 30 days of the index procedure. Conclusion: In this study, similar 12-month event rates were observed for both BRS types after implantation for the treatment of ACS.

Involved external institutions

Justus-Liebig-Universität Gießen DE Germany (DE) National Heart Research Institute Singapore (NHRIS) SG Singapore (SG) Kerckhoff-Klinik DE Germany (DE) Deutsches Herzzentrum München DE Germany (DE) Carl von Ossietzky Universität Oldenburg DE Germany (DE) St.-Johannes-Hospital DE Germany (DE)

How to cite

APA:

Nef, H.M., Wiebe, J., Schmidt, G., Möllmann, H., Boeder, N.F., Dörr, O.,... Hamm, C.W. (2020). Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome. Herz, 45, 95-104. https://doi.org/10.1007/s00059-019-4822-7

MLA:

Nef, H. M., et al. "Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome." Herz 45 (2020): 95-104.

BibTeX: Download